Management tracks: Spark, Cabaletta

Spark Therapeutics Inc. (NASDAQ:ONCE) said in an SEC filing that COO John Furey will resign, effective Jan. 1. He will remain a consultant for the gene therapy company through June 28.

Cabaletta Bio Inc. (Radnor, Pa.) appointed CAR T cell pioneer Carl June to its scientific advisory board, in addition to Jay Siegel and Gwendolyn Binder. The University of Pennsylvania spinout emerged from stealth on Nov. 8 with a $38 million series A to develop chimeric auto-antibody receptor (CAAR) T cell therapies (see "Cabaletta Spins Out of Penn With CAR T Autoimmune Therapy, $38M Series A")...